160:@0.085199:0.957873:0.109688:0.957873:0.109688:0.938882:0.085199:0.938882:0.007305:0.008593:0.008591
6:@0.038824:0.497523:0.060302:0.497523:0.060302:0.450045:0.038824:0.450045:0.021478
CHAPTER 6:@0.117647:0.067219:0.190817:0.067219:0.190817:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008716
able to detect a total of 20 supplementary breakpoints that connect V, D or J segments :@0.117647:0.121273:0.857093:0.121273:0.857093:0.100900:0.117647:0.100900:0.009108:0.010911:0.005182:0.009039:0.005478:0.006209:0.011048:0.005478:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005478:0.009291:0.005478:0.006209:0.010820:0.006551:0.009402:0.005250:0.005478:0.010843:0.006209:0.005478:0.010432:0.010432:0.005478:0.007510:0.011071:0.011048:0.011162:0.005182:0.009039:0.017485:0.009039:0.011391:0.006551:0.009085:0.008400:0.009724:0.005478:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.005478:0.006620:0.011391:0.008811:0.006437:0.005478:0.008994:0.010843:0.011756:0.011596:0.009108:0.009108:0.006437:0.005478:0.011482:0.004497:0.005478:0.016139:0.005478:0.010843:0.007807:0.005478:0.006871:0.005478:0.007873:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.007670:0.004109
in the Ig or TR loci, which represent potential MRD targets. Of these, 8 belong to the :@0.117647:0.141852:0.856981:0.141852:0.856981:0.121479:0.117647:0.121479:0.005615:0.011756:0.005912:0.006620:0.011299:0.009039:0.005912:0.006483:0.009861:0.005912:0.010843:0.007807:0.005912:0.013354:0.013376:0.005912:0.005182:0.011276:0.008994:0.005339:0.004497:0.005912:0.014792:0.011459:0.005547:0.008765:0.011459:0.005912:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.005912:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.005912:0.019608:0.013376:0.016139:0.005912:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.004497:0.005912:0.016298:0.006209:0.005912:0.006620:0.011299:0.009039:0.007875:0.008743:0.004497:0.005912:0.010432:0.005912:0.011251:0.008950:0.005182:0.010843:0.011459:0.009861:0.005912:0.006209:0.011048:0.005912:0.006620:0.011299:0.009039:0.004109
B-ALL5 sample, 4 to the T-ALL1 sample, 3 to the B-ALL4 sample, 2 to the B-ALL2, 2 :@0.117647:0.162431:0.857148:0.162431:0.857148:0.142058:0.117647:0.142058:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.005661:0.007944:0.009085:0.017280:0.011162:0.005182:0.008743:0.004497:0.005661:0.010432:0.005661:0.006209:0.011048:0.005661:0.006620:0.011299:0.009039:0.005661:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.005661:0.007944:0.009085:0.017280:0.011162:0.005182:0.008743:0.004497:0.005661:0.010432:0.005661:0.006209:0.011048:0.005661:0.006620:0.011299:0.009039:0.005661:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.005661:0.007944:0.009085:0.017280:0.011165:0.005182:0.008743:0.004497:0.005661:0.010432:0.005661:0.006209:0.011048:0.005661:0.006620:0.011302:0.009039:0.005661:0.012646:0.007533:0.014929:0.011619:0.011619:0.010432:0.004497:0.005661:0.010432:0.004109
to the T-ALL4 sample and 1 to the T-ALL3 sample (:@0.117647:0.183009:0.561674:0.183009:0.561674:0.162636:0.117647:0.162636:0.006209:0.011048:0.005090:0.006620:0.011299:0.009039:0.005090:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.005090:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.005090:0.009085:0.011596:0.011391:0.005090:0.010432:0.005090:0.006209:0.011048:0.005090:0.006620:0.011299:0.009039:0.005090:0.011801:0.007533:0.014929:0.011619:0.011619:0.010432:0.005090:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.005090:0.006939
Table 1, Supplementary Table 3:@0.561719:0.183009:0.841482:0.183009:0.841482:0.161876:0.561719:0.161876:0.011413:0.009679:0.011528:0.005935:0.009473:0.004976:0.010911:0.005433:0.004976:0.010455:0.011893:0.011731:0.011779:0.005935:0.009268:0.018102:0.009268:0.012053:0.007053:0.009656:0.009359:0.009998:0.004976:0.011413:0.009679:0.011528:0.005935:0.009473:0.004976:0.010911
). :@0.841505:0.183009:0.857050:0.183009:0.857050:0.162636:0.841505:0.162636:0.006939:0.004497:0.004109
Furthermore, there are a total of 12 validated SVs that, even though they do not connect :@0.117647:0.203588:0.857136:0.203588:0.857136:0.183215:0.117647:0.183215:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004132:0.006620:0.011299:0.009039:0.007442:0.009039:0.004132:0.009085:0.007442:0.009039:0.004132:0.009291:0.004102:0.006209:0.010820:0.006551:0.009405:0.005250:0.004132:0.010843:0.006209:0.004132:0.010432:0.010432:0.004132:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.004132:0.010112:0.015089:0.007670:0.004132:0.006620:0.011391:0.008811:0.006437:0.004497:0.004132:0.009334:0.009635:0.009039:0.011756:0.004132:0.006620:0.011299:0.010820:0.011413:0.009930:0.011459:0.004132:0.006620:0.011302:0.009334:0.009724:0.004132:0.011322:0.011048:0.004132:0.011596:0.010820:0.006437:0.004132:0.008994:0.010843:0.011756:0.011596:0.009108:0.009108:0.006437:0.004109
V(D)J segments, could be used as patient-specific biomarkers with specific break-junc-:@0.117647:0.222991:0.852941:0.222991:0.852941:0.202618:0.117647:0.202618:0.015089:0.006939:0.016139:0.006939:0.006871:0.004885:0.007873:0.009039:0.009861:0.017483:0.009039:0.011391:0.006437:0.007670:0.004497:0.004885:0.008994:0.010820:0.011550:0.005182:0.011391:0.004885:0.011254:0.009039:0.004885:0.011413:0.007875:0.009108:0.011391:0.004885:0.009291:0.007670:0.004885:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011502:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004885:0.010820:0.005547:0.010843:0.017577:0.009087:0.007601:0.010272:0.009039:0.007624:0.007670:0.004885:0.014723:0.005273:0.006620:0.011459:0.004885:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004885:0.010820:0.007442:0.009291:0.009402:0.010523:0.007533:0.004953:0.011413:0.011596:0.008930:0.007533
tion assays in a similar fashion as previous studies:@0.117647:0.243570:0.533206:0.243570:0.533206:0.223197:0.117647:0.223197:0.006437:0.005547:0.010843:0.011756:0.004109:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004109:0.005615:0.011756:0.004109:0.009291:0.004109:0.007601:0.005615:0.017645:0.005750:0.005433:0.009085:0.007807:0.004109:0.006209:0.009291:0.007556:0.011459:0.005547:0.010843:0.011756:0.004109:0.009291:0.007670:0.004109:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.004109:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670
69,409:@0.533206:0.235953:0.566236:0.235953:0.566236:0.224076:0.533206:0.224076:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. :@0.566235:0.243570:0.574841:0.243570:0.574841:0.223197:0.566235:0.223197:0.004497:0.004109
Figure 4. Ig and TCR coverage plots: :@0.117647:0.896967:0.385337:0.896967:0.385337:0.879676:0.117647:0.879676:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.003735:0.008927:0.004445:0.003735:0.005902:0.008591:0.003735:0.007900:0.009955:0.009712:0.003735:0.010739:0.012084:0.011579:0.003735:0.007433:0.009581:0.007863:0.007583:0.007116:0.008012:0.008423:0.007751:0.003735:0.009637:0.004856:0.009338:0.005939:0.006574:0.004445:0.003287
Coverage plots for the samples B-ALL1, B-ALL2, B-ALL3, B-ALL4, :@0.385759:0.896967:0.856256:0.896967:0.856256:0.880298:0.385759:0.880298:0.012270:0.008890:0.007881:0.007396:0.006462:0.007527:0.007900:0.007396:0.003810:0.009133:0.004240:0.008853:0.005267:0.006275:0.003810:0.004931:0.008871:0.006387:0.003810:0.005416:0.009245:0.007396:0.003810:0.006499:0.007433:0.014138:0.009133:0.004240:0.007396:0.006275:0.003810:0.010347:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003810:0.010347:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003810:0.010347:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003810:0.010347:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003362
B-ALL5, T-ALL1, T-ALL2, T-ALL3, T-ALL4, and T-ALL5 for the :@0.117647:0.911519:0.567174:0.911519:0.567174:0.894850:0.117647:0.894850:0.010347:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003138:0.009656:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003138:0.009658:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003138:0.009656:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003138:0.009656:0.006163:0.012214:0.009506:0.009506:0.008535:0.003679:0.003138:0.007435:0.009488:0.009320:0.003138:0.009656:0.006163:0.012214:0.009506:0.009506:0.008535:0.003138:0.004931:0.008871:0.006387:0.003138:0.005416:0.009245:0.007396:0.003362
(A):@0.566890:0.911519:0.591711:0.911519:0.591711:0.894229:0.566890:0.894229:0.006238:0.012345:0.006238
 IGH, :@0.591711:0.911519:0.634088:0.911519:0.634088:0.894850:0.591711:0.894850:0.003138:0.005584:0.012831:0.013783:0.003679:0.003362
(B) :@0.633852:0.911519:0.660877:0.911519:0.660877:0.894229:0.633852:0.894229:0.006238:0.011262:0.006238:0.003287
IGK, :@0.660653:0.911519:0.698006:0.911519:0.698006:0.894850:0.660653:0.894850:0.005584:0.012831:0.011897:0.003679:0.003362
(C) :@0.697776:0.911519:0.725622:0.911519:0.725622:0.894229:0.697776:0.894229:0.006238:0.012084:0.006238:0.003287
IGL, :@0.725397:0.911519:0.760360:0.911519:0.760360:0.894850:0.725397:0.894850:0.005584:0.012831:0.009506:0.003679:0.003362
(D):@0.760130:0.911519:0.786127:0.911519:0.786127:0.894229:0.760130:0.894229:0.006238:0.013522:0.006238
 TRA and :@0.786127:0.911519:0.856313:0.911519:0.856313:0.894850:0.786127:0.894850:0.003138:0.010926:0.011169:0.012214:0.003138:0.007433:0.009488:0.009320:0.003362